Understanding the Market | CARDIOFLOW-B fell nearly 7% before earnings, will release mid-term results after today's trading session, previously expected to narrow losses by up to 83% in the first half of the year
CARDIOFLOW-B fell nearly 7% before earnings, and as of the time of publication, it was down 4.2%, trading at HKD 1.37, with a transaction volume of HKD 11.3101 million. In terms of news, CARDIOFLOW plans to hold a board meeting on August 28 to approve its interim results. The company previously issued a profit warning, expecting a net loss of no more than RMB 10 million in the first half of 2025, a year-on-year decrease of no less than 83%. The announcement stated that the reduction in net loss was mainly due to the sales of the VitaFlow Liberty transcatheter aortic valve and its retrievable delivery system in more than 20 countries/regions overseas, with overseas revenue increasing more than twofold; the commercialization progress of the AnchorMan left atrial appendage occluder system and its guiding system in China is steadily advancing, and it has obtained CE marking for commercialization in Europe, contributing to revenue growth; continuous optimization of resource allocation and other measures have further improved operational efficiency; and the joint venture 4C Medical completed Series D financing, resulting in a decrease in the group's shareholding, which is considered as gains from the sale of equity
According to Zhitong Finance APP, CARDIOFLOW-B (02160) fell nearly 7% before its earnings report, and as of the time of writing, it has dropped 4.2%, trading at HKD 1.37, with a transaction volume of HKD 11.3101 million.
In terms of news, CARDIOFLOW plans to hold a board meeting on August 28 to approve its interim results. The company previously issued a profit warning, expecting a net loss of no more than RMB 10 million in the first half of 2025, a year-on-year decrease of no less than 83%.
The announcement stated that the reduction in net loss is mainly due to the VitaFlow Liberty transcatheter aortic valve and retrievable delivery system achieving sales in more than 20 countries/regions overseas, with overseas revenue increasing more than twofold; the commercial progress of the AnchorMan left atrial appendage occluder system and its guiding system in China is steadily advancing, and it has obtained CE marking for commercialization in Europe, contributing to revenue growth; continuous optimization of resource allocation and other measures further enhance operational efficiency; and the joint venture 4C Medical completed Series D financing, resulting in a decrease in the group's shareholding, which is treated as a gain from the sale of equity
